Viatris Common Stock Net 2010-2024 | VTRS

Viatris common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
  • Viatris common stock net for the quarter ending September 30, 2024 was $0.012B, a 0.82% increase year-over-year.
  • Viatris common stock net for 2023 was $0.012B, a 0.83% increase from 2022.
  • Viatris common stock net for 2022 was $0.012B, a 0% decline from 2021.
  • Viatris common stock net for 2021 was $0.012B, a 0% decline from 2020.
Viatris Annual Common Stock Net
(Millions of US $)
2023 $12
2022 $12
2021 $12
2020 $12
2019 $6
2018 $6
2017 $6
2016 $6
2015 $6
2014 $273
2013 $272
2012 $270
2011 $265
2010 $263
2009 $198
Viatris Quarterly Common Stock Net
(Millions of US $)
2024-06-30 $12
2024-03-31 $12
2023-12-31 $12
2023-09-30 $12
2023-06-30 $12
2023-03-31 $12
2022-12-31 $12
2022-09-30 $12
2022-06-30 $12
2022-03-31 $12
2021-12-31 $12
2021-09-30 $12
2021-06-30 $12
2021-03-31 $12
2020-12-31 $12
2020-09-30 $6
2020-06-30 $6
2020-03-31 $6
2019-12-31 $6
2019-09-30 $6
2019-06-30 $6
2019-03-31 $6
2018-12-31 $6
2018-09-30 $6
2018-06-30 $6
2018-03-31 $6
2017-12-31 $6
2017-09-30 $6
2017-06-30 $6
2017-03-31 $6
2016-12-31 $6
2016-09-30 $6
2016-06-30 $6
2016-03-31 $6
2015-12-31 $6
2015-09-30 $6
2015-06-30 $6
2015-03-31 $6
2014-12-31 $273
2014-09-30 $273
2014-06-30 $273
2014-03-31 $273
2013-12-31 $272
2013-09-30 $271
2013-06-30 $271
2013-03-31 $271
2012-12-31 $270
2012-09-30 $267
2012-06-30 $266
2012-03-31 $266
2011-12-31 $265
2011-09-30 $265
2011-06-30 $265
2011-03-31 $264
2010-12-31 $263
2010-09-30 $200
2010-06-30 $200
2010-03-31 $199
2009-12-31 $198
2009-09-30 $198
2009-06-30 $198
2009-03-31 $198
Sector Industry Market Cap Revenue
Medical Medical Services $15.469B $15.427B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $98.015B 12.16
Cencora (COR) United States $48.948B 18.05
DiDi Global (DIDIY) China $23.622B 0.00
ICON (ICLR) Ireland $17.731B 15.79
Natera (NTRA) United States $16.587B 0.00
Avantor (AVTR) United States $15.375B 23.05
Revvity (RVTY) United States $14.905B 25.89
BioMerieux (BMXMF) France $13.087B 0.00
CochLear (CHEOY) Australia $12.590B 0.00
Solventum (SOLV) United States $12.509B 0.00
Medpace Holdings (MEDP) United States $11.276B 31.77
Charles River Laboratories (CRL) United States $11.014B 21.28
Doximity (DOCS) United States $10.815B 64.01
HealthEquity (HQY) United States $8.629B 46.83
Sonic Healthcare (SKHHY) Australia $8.542B 0.00
Bausch + Lomb (BLCO) Canada $7.043B 32.79
Life Times (LTH) United States $5.170B 34.22
Sotera Health (SHC) United States $4.557B 24.38
Organon (OGN) United States $4.131B 4.17
Surgery Partners (SGRY) United States $3.859B 42.76
BrightSpring Health Services (BTSG) United States $3.408B 72.48
PACS (PACS) United States $3.251B 0.00
Alignment Healthcare (ALHC) United States $2.620B 0.00
Concentras Parent (CON) United States $2.500B 0.00
Ardent Health Partners (ARDT) United States $2.337B 0.00
Premier (PINC) United States $2.292B 11.44
GeneDx Holdings (WGS) United States $2.137B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
GoodRx Holdings (GDRX) United States $1.856B 48.90
Teladoc Health (TDOC) United States $1.589B 0.00
Progyny (PGNY) United States $1.499B 26.37
Pediatrix Medical (MD) United States $1.353B 13.24
Establishment Labs Holdings (ESTA) $1.292B 0.00
CareDx (CDNA) United States $1.268B 0.00
AMN Healthcare Services Inc (AMN) United States $1.104B 7.49
Embecta (EMBC) United States $0.897B 5.98
InnovAge Holding (INNV) United States $0.813B 0.00
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
Agilon Health (AGL) United States $0.757B 0.00
SBC Medicals (SBC) United States $0.706B 0.00
Auna S.A (AUNA) Luxembourg $0.514B 0.00
Sonida Senior Living (SNDA) United States $0.469B 0.00
DocGo (DCGO) United States $0.409B 15.38
Enhabit (EHAB) United States $0.397B 34.30
COMPASS Pathways (CMPS) United Kingdom $0.373B 0.00
LifeMD (LFMD) United States $0.252B 0.00
Sera Prognostics (SERA) United States $0.225B 0.00
ModivCare (MODV) United States $0.221B 12.05
Beauty Health (SKIN) United States $0.202B 0.00
Biodesix (BDSX) United States $0.199B 0.00
Nutex Health (NUTX) United States $0.160B 0.00
MultiPlan (MPLN) United States $0.137B 0.00
Ascend Wellness Holdings (AAWH) United States $0.129B 0.00
So-Young (SY) China $0.089B 21.63
Singular Genomics Systems (OMIC) United States $0.057B 0.00
Harvard Apparatus Regenerative Technology (HRGN) United States $0.055B 0.00
OncoCyte (OCX) United States $0.048B 0.00
NeueHealth (NEUE) United States $0.042B 1.11
Co-Diagnostics (CODX) United States $0.036B 0.00
IceCure Medical (ICCM) Israel $0.030B 0.00
Pheton Holdings (PTHL) China $0.028B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.028B 0.00
Oncology Institute (TOI) United States $0.020B 0.00
SeaStar Medical Holding (ICU) United States $0.011B 0.00
XWELL (XWEL) United States $0.009B 0.00
Intelligent Bio Solutions (INBS) United States $0.007B 0.00
BioNexus Gene Lab (BGLC) $0.006B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00